Cargando…

Cell fate takes a slug in BRCA1-associated breast cancer

Understanding why BRCA1 mutation carriers have a predilection for developing clinically aggressive basal-like breast tumors could inform the development of targeted treatment or prevention strategies. Analysis of both mouse and human mammary epithelial cells has identified a role for BRCA1 in orches...

Descripción completa

Detalles Bibliográficos
Autores principales: Lindeman, Geoffrey J, Visvader, Jane E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3219185/
https://www.ncbi.nlm.nih.gov/pubmed/21489318
http://dx.doi.org/10.1186/bcr2840
_version_ 1782216791864377344
author Lindeman, Geoffrey J
Visvader, Jane E
author_facet Lindeman, Geoffrey J
Visvader, Jane E
author_sort Lindeman, Geoffrey J
collection PubMed
description Understanding why BRCA1 mutation carriers have a predilection for developing clinically aggressive basal-like breast tumors could inform the development of targeted treatment or prevention strategies. Analysis of both mouse and human mammary epithelial cells has identified a role for BRCA1 in orchestrating differentiation. The ability to isolate discrete epithelial subpopulations from mammary tissue has recently directed attention to luminal progenitor cells - the descendants of mammary stem cells - as the likely 'cells-of-origin' in BRCA1-associated breast cancer. A new publication has confirmed the importance of aberrant luminal cells as key culprits and provided insights on how BRCA1 haploinsufficiency biases luminal cells toward a basal-like fate through aberrant expression of the transcription factor SLUG.
format Online
Article
Text
id pubmed-3219185
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-32191852011-11-18 Cell fate takes a slug in BRCA1-associated breast cancer Lindeman, Geoffrey J Visvader, Jane E Breast Cancer Res Viewpoint Understanding why BRCA1 mutation carriers have a predilection for developing clinically aggressive basal-like breast tumors could inform the development of targeted treatment or prevention strategies. Analysis of both mouse and human mammary epithelial cells has identified a role for BRCA1 in orchestrating differentiation. The ability to isolate discrete epithelial subpopulations from mammary tissue has recently directed attention to luminal progenitor cells - the descendants of mammary stem cells - as the likely 'cells-of-origin' in BRCA1-associated breast cancer. A new publication has confirmed the importance of aberrant luminal cells as key culprits and provided insights on how BRCA1 haploinsufficiency biases luminal cells toward a basal-like fate through aberrant expression of the transcription factor SLUG. BioMed Central 2011 2011-04-06 /pmc/articles/PMC3219185/ /pubmed/21489318 http://dx.doi.org/10.1186/bcr2840 Text en Copyright ©2011 BioMed Central Ltd
spellingShingle Viewpoint
Lindeman, Geoffrey J
Visvader, Jane E
Cell fate takes a slug in BRCA1-associated breast cancer
title Cell fate takes a slug in BRCA1-associated breast cancer
title_full Cell fate takes a slug in BRCA1-associated breast cancer
title_fullStr Cell fate takes a slug in BRCA1-associated breast cancer
title_full_unstemmed Cell fate takes a slug in BRCA1-associated breast cancer
title_short Cell fate takes a slug in BRCA1-associated breast cancer
title_sort cell fate takes a slug in brca1-associated breast cancer
topic Viewpoint
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3219185/
https://www.ncbi.nlm.nih.gov/pubmed/21489318
http://dx.doi.org/10.1186/bcr2840
work_keys_str_mv AT lindemangeoffreyj cellfatetakesasluginbrca1associatedbreastcancer
AT visvaderjanee cellfatetakesasluginbrca1associatedbreastcancer